% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

  • bhakes_98 bhakes_98 Nov 15, 2012 10:11 AM Flag

    SCLN - No debt...

    $90MM in cash, $40 stock buy back program with $16MM left. While SCLN reduced 2012 revenues it'll still be more than 2011. SCLN's main driver is Zadaxin but has a promising pipeline.

    The market cap is $240MM less cash leaves a value of $150MM, that is roughly 6 times earnings. SCLN is way oversold at $4.3 pps.


9.25+0.08(+0.87%)Nov 27 1:00 PMEST